Henghui Pharmaceutical

Hengrui Pharma is a large Chinese innovative pharmaceutical company focused on discovery, development, manufacturing, and commercialization of branded and innovative medicines. The company markets numerous products in China and maintains a broad global pipeline spanning oncology, metabolic and cardiovascular disease, immunology and respiratory disease, neuroscience, ophthalmology, hematology, infectious disease, and pain. Hengrui has built substantial internal R&D capabilities, including platforms in small molecules, monoclonal antibodies, bispecifics, ADCs, peptides, radioligand therapy, PROTACs, and AI-enabled drug discovery. Its best-known assets include camrelizumab, pyrotinib, rivoceranib/apatinib, trastuzumab rezetecan, and multiple next-generation metabolic and cardiovascular programs. The company is publicly traded in mainland China and Hong Kong and has become increasingly active in global partnering and out-licensing transactions.